Charles River Laboratories Intl. Inc vs Devon Energy Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $229.81 (market cap $11.14B), while Devon Energy Corp trades at $43.08 (market cap $50.44B). The key difference: Devon Energy Corp is far larger — about 4.5× Charles River Laboratories Intl. Inc's market cap, and Devon Energy Corp pays a 2.38% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | DVN | |
|---|---|---|
Market Cap | $11.14B | $50.44B |
Sector | Health | Energy |
52-Week High | $233.60 | $52.07 |
52-Week Low | $145.57 | $31.74 |
Enterprise Value | $14.00B | $57.22B |
Dividend Yield | — | 2.38% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Devon Energy (DVN) trades at $43.73, up 3.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, with Q2 results pending. The company maintains solid profitability with a 13.71% net margin and robust cash flow, supported by the Coterra acquisition targeting $2 billion in synergies by 2027. Debt-to-asset ratio improved to 26.54% in 2025, reflecting disciplined financial management.
Outlook remains positive with a consensus price target of $60.55, implying significant upside. Key opportunities include synergy realization and free cash flow growth, while risks involve oil price volatility and activist investor pressure for asset sales. The stock offers value with a P/E of 12.18, below sector averages, but investors should monitor Q2 earnings due August 4 for confirmation of growth trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →